Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced a 1-for-30 reverse stock split for its Class A and Class B common stock, effective June 12, 2024. This move aims to raise the company's share price to meet NYSE listing requirements. Post-split, Class A common stock will reduce from approximately 156.76 million to about 5.23 million shares, and Class B from 19.62 million to roughly 654,000 shares. Trading on a post-split basis begins on June 13, 2024, under the symbol 'RBOT'. The split will uniformly affect all stockholders without changing ownership percentages, except for fractional shares, which will be paid in cash. Warrants will also be adjusted, with the exercise price changing to $345 per share.
Vicarious Surgical Inc. (RBOT) reported its first-quarter 2024 financial results, showcasing a decrease in operating expenses, R&D expenses, general and administrative expenses, and sales and marketing expenses compared to the previous year. The company reported an adjusted net loss of $15.1 million, equating to a loss of $0.09 per share, and a GAAP net loss of $17.0 million, or a net loss per share of $0.10 for the same period. Vicarious Surgical had $84.1 million in cash and investments as of March 31, 2024, with a cash burn rate of $14.1 million for the first quarter. The company reiterated its expected full-year 2024 cash burn of approximately $50 million.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
